FatiAbGen develops monoclonal antibody-based therapies that utilize advanced linker technology to enhance payload delivery to solid tumors while minimizing immunogenicity and toxicity. This approach addresses the challenges of treating various cancers and immunological disorders, providing patients with effective therapeutic options.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumor therapies struggle with effective payload delivery, leading to insufficient efficacy and significant off-target toxicity due to poor tumor penetration and systemic exposure. Traditional monoclonal antibody approaches can also elicit unwanted immune responses, further limiting their therapeutic potential.
Solution
FatiAbGen is developing a pipeline of monoclonal antibody-based therapies engineered with advanced linker technology to improve payload delivery to solid tumors. Their approach aims to enhance tumor penetration and minimize systemic toxicity, leading to more effective and safer cancer treatments. By optimizing the antibody-drug conjugate (ADC) design, FatiAbGen seeks to reduce immunogenicity and improve the therapeutic index of their oncology and immunology assets. The company is focused on creating novel antibody assets to address unmet needs in oncology and immunological disorders.
Target Audience
The primary target audience includes patients with solid tumors and immunological disorders, as well as pharmaceutical companies seeking innovative antibody-based therapeutics.
Features
- Monoclonal antibody-based therapies
- Advanced linker technology for enhanced payload delivery
- Minimized immunogenicity and toxicity
- Focus on solid tumor penetration
- Pipeline of oncology and immunology assets